阿哌沙班用于机器人二尖瓣修复术后抗凝
本研究回顾性分析2008年1月至2019年10月间666例孤立性机器人二尖瓣修复术患者,排除转开放及未抗凝或仅用氯吡格雷者40例,最终纳入626例,比较阿哌沙班与华法林术后抗凝的结局。阿哌沙班组再入院率较高(12% vs 6%,P=0.02),主要由术后房颤驱动(5% vs 1%,P=0.01);两组在院内并发症、出血、血栓栓塞事件及3年总体死亡率方面无差异。结论认为阿哌沙班用于微创机器人二尖瓣修复术后抗凝是安全的,出血和血栓栓塞率与华法林相似。
要点
- 阿哌沙班组再入院率12%高于华法林组6%(P=0.02),主要由术后房颤驱动(5% vs 1%,P=0.01)。
- 两组院内并发症(包括卒中)、出血及血栓栓塞事件无差异,3年总体死亡率无差异。
- 阿哌沙班组99%(126/127)联用阿司匹林,华法林组79%(395/499)联用阿司匹林。
核心结论
- 微创机器人二尖瓣修复术后使用阿哌沙班抗凝是安全的,出血和血栓栓塞率与华法林治疗患者相似。
研究设计与样本
- 回顾性研究,纳入2008年1月至2019年10月间接受孤立性机器人二尖瓣修复术的666例患者,排除转胸骨切开及出院未抗凝或仅用氯吡格雷者40例,最终分析626例。
主要发现
- 626例患者中位年龄58岁(四分位距51-66),71%为男性,1%(n=9)有房颤;80%(n=499)出院带华法林,20%(n=127)带阿哌沙班。
- 阿哌沙班组99%(126/127)出院时联用阿司匹林,华法林组79%(n=395)联用阿司匹林。
- 阿哌沙班组女性比例更高(36%[46/127] vs 27%[136/499],P=0.047),其余基线特征相似。
- 阿哌沙班组再入院率更高(12%[15/127] vs 6%[30/499],P=0.02),主要由术后房颤驱动(5%[6/127] vs 1%[5/499],P=0.01)。
- 两组其他并发症(包括出血和血栓栓塞事件)及3年内总体死亡率无差异;排除出院未用阿司匹林者后结果不变。
临床怎么用
- 原文结论认为阿哌沙班用于微创机器人二尖瓣修复术后抗凝是安全的,出血和血栓栓塞率与华法林相似;原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is no consensus regarding postoperative anticoagulation after mitral valve repair (MVRep). We compared the outcomes of post-MVRep anticoagulation with apixaban compared to warfarin. METHODS: We reviewed data of 666 patients who underwent isolated robotic MVRep between January 2008 and October 2019. We excluded patients who had conversion to sternotomy and those discharged without anticoagulation or on clopidogrel (n = 40). Baseline and intraoperative characteristics and antiplatelet/anticoagulation records were collected. In-hospital and post-discharge complications and overall survival were compared. RESULTS: Among the 626 studied patients the median age was 58 years (interquartile range, 51-66), 71% were male, and 1% (n = 9) had atrial fibrillation. Eighty percent (n = 499) were discharged on warfarin and 20% on apixaban (n = 127). Almost all patients (126 of 127, 99%) in the apixaban group were also on aspirin at discharge, whereas in the warfarin group only 79% (n = 395) were also on aspirin at discharge. Baseline characteristics were similar, except that the apixaban group had more female patients (46 of 127, 36% vs 136 of 499, 27%, P = .047). There were no differences in in-hospital complications, including stroke. Readmission rate was higher in the apixaban group (15 of 127, 12% vs 30 of 499, 6%, P = .02), driven mostly by postoperative atrial fibrillation (6 of 127 [5%] vs 5 of 499 [1%], respectively; P = .01). There was no difference in other complications (including bleeding and thromboembolic events), or overall mortality within 3 years. Exclusion of patients who did not receive aspirin at discharge did not affect the results. CONCLUSIONS: Anticoagulation with apixaban after minimally invasive robotic MVRep is safe and has similar rates of bleeding and thromboembolism compared to patients treated with warfarin.
引用
- Mazur PK, Arghami A, Macielak SA, et al. Apixaban for Anticoagulation After Robotic Mitral Valve Repair. Ann Thorac Surg. 2022. PMID: 35973484. doi:10.1016/j.athoracsur.2022.07.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。